- © Baliopharm AG 2023
Baliopharm / Advisory Board
Baliopharm´s R&D development programs are supported by close academic collaborations with experienced key opinion leaders in signal transduction, oncology, bispecific antibodies, and cytokine-based therapeutics.
Professor Gundram Jung, MD
Gundram Jung, MD, Professor, is head of the Section for Experimental Antibody Therapy within the Department of Immunology at the University of Tübingen. During his medical training he specialized in internal medicine, hematology and medical oncology. He is one of the pioneers in the bispecific antibody field and, among others, developed the concept of target cell restricted T cell activation with bispecific antibodies. Combining his expertise in clinical oncology with his scientific interest, Prof. Jung is committed to improve the quality and speed of the translational process for antitumor antibodies in general and bispecific antibodies in particular.
Professor Klaus Pfizenmaier, PhD
Klaus Pfizenmaier, PhD, is Professor and Director of the Institute of Cell Biology and Immunology at the University Stuttgart. He has more than 30 years of active research experience in the field of cellular immunology, cell biology, cytokine function and signal transduction mechanisms as well as in the development of cytokine-based therapeutics and receptor selective antagonists with around 200 scientific publications. Klaus Pfizenmaier is currently also a Board member of the Center Systems Biology and Prodecan of the Faculty for Energy Technology, Process-Engineering and Bio-Engineering in Stuttgart. Prior to his current position, he was Head of the Clinical Research Group “Biological Regulation of Host-Tumor-Interactions” of the Max-Planck-Society at the University Clinic Göttingen. Klaus Pfizenmaier received his PhD in 1976 from the Institute of Microbiology in Mainz and habilitated in Immunology in 1982.